- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 20-F/A Annual report (foreign)
- 4.69 Ex - 4.69
- 4.70 Ex -4.70
- 4.71 Ex - 4.71
- 4.72 Ex - 4.72
- 4.73 Ex - 4.73
- 4.74 Ex - 4.74
- 4.75 Ex - 4.75
- 4.76 Ex - 4.76
- 4.77 Ex - 4.77
- 4.78 Ex - 4.78
- 4.79 Ex - 4.79
- 4.80 Ex - 4.80
- 4.81 Ex - 4.81
- 4.82 Ex - 4.82
- 4.83 Ex - 4.83
- 8.1 Ex - 8.1
- 12.1 Ex - 12.1
- 12.2 Ex - 12.2
- 13.1 Ex - 13.1
- 13.2 Ex - 13.2
- 2.1 EX-2.1
- 15.1 Consent of Independent Registered Public Accounting Firm
- Download Excel data file
- View Excel data file
EXHIBIT 13.2
INTELLIPHARMACEUTICS INTERNATIONAL INC.
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002
In connection with the Amendment No. 1 to the Annual Report of Intellipharmaceutics International Inc. (the “Company”) on Form 20-F for the period ending November 30, 2021 (the “Report”), I, Amina Odidi, Acting Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
|
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: March 31, 2022 | By: | /s/ Amina Odidi | |
|
| Amina Odidi | |
Acting Chief Financial Officer | |||
(Principal Financial Officer) |